Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act
Literal federal measure citations: H.R.7635
2026 · 3rd Quarter (July 1 - Sep 30)
BRISTOL-MYERS SQUIBB COMPANY
Filed by BRISTOL-MYERS SQUIBB COMPANY.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- Not reported
- Expenses
- $3,050,000.00
- Registrant
- BRISTOL-MYERS SQUIBB COMPANY
- Filing UUID
- 2ba12235-d88d-4cb5-815c-20e5961d8c83
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions Discussions regarding condification of MFN policies Fixed dose conbination drugs and general research and development Prescription Information Modernization Act of 2026 (PIMA)
Literal federal measure citations: H.R.1492, H.R.4299, H.R.5509
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation
Intellectual Property Reform concerning bio-pharmaceutical industry
International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues Issues concerning competitive trade
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.